HYPOTHYROIDISM COULD BE A POTENTIAL FACTOR TO PROLONG SUBCUTANEOUS NODULES OF EXENATIDE ONCE WEEKLY: A CASE REPORT.
Journal
AACE clinical case reports
ISSN: 2376-0605
Titre abrégé: AACE Clin Case Rep
Pays: United States
ID NLM: 101670593
Informations de publication
Date de publication:
Historique:
received:
24
08
2018
accepted:
27
11
2018
entrez:
23
1
2020
pubmed:
23
1
2020
medline:
23
1
2020
Statut:
epublish
Résumé
Exenatide once weekly (ExeOW) is one of the long-acting glucagon-like peptide 1 receptor agonists. Embedding exenatide in poly(D,L-lactide-co-glycolide) microspheres enables the once-weekly subcutaneous injection of exenatide as a treatment for diabetes. We report a case of a patient with type 2 diabetes and hypothyroidism who developed long-standing subcutaneous nodules after treatment by ExeOW injection. Case report and review of the literature. A 57-year-old Japanese man with type 2 diabetes treated with ExeOW and primary hypothyroidism. We observed multiple subcutaneous nodules remaining at the ExeOW injection site for >10 weeks. As the patient's thyroid hormone levels normalized, these nodules decreased and disappeared, and his hemoglobin A1c levels improved. The patient's clinical course suggests that the hydrolysis of ExeOW at the site of injection may be inhibited by concomitant hypothyroidism, in which glycosaminoglycans including hyaluronic acid are known to accumulate (including in the skin). This case may indicate that hypothyroidism prolongs the existence of subcutaneous nodules from ExeOW treatment.
Identifiants
pubmed: 31967033
doi: 10.4158/ACCR-2018-0418
pmc: PMC6876937
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e197-e200Informations de copyright
Copyright © 2019 AACE.
Déclaration de conflit d'intérêts
DISCLOSURE The authors have no multiplicity of interest to disclose.
Références
J Cutan Pathol. 2014 Jan;41(1):63-5
pubmed: 24224897
Diabetes Spectr. 2015 Nov;28(4):283-8
pubmed: 26597395
J Clin Invest. 1982 Nov;70(5):1066-73
pubmed: 6813355
Diabetes Technol Ther. 2011 Nov;13(11):1145-54
pubmed: 21751887
Dermatoendocrinol. 2011 Jul;3(3):211-5
pubmed: 22110782
Diabetes Metab Syndr Obes. 2015 May 18;8:241-53
pubmed: 26056482
Lancet. 2008 Oct 4;372(9645):1240-50
pubmed: 18782641
Biochim Biophys Acta. 1962 Mar 26;58:27-33
pubmed: 14498394
Clin Chem. 2008 Feb;54(2):240-8
pubmed: 18223132
Am J Dermatopathol. 2014 Jun;36(6):510-2
pubmed: 24366197
Endocrinology. 2007 Jan;148(1):54-62
pubmed: 17068136
Acta Endocrinol (Copenh). 1986 Sep;113(1):56-8
pubmed: 3094309
Nat Rev Endocrinol. 2012 Dec;8(12):728-42
pubmed: 22945360
Adv Drug Deliv Rev. 1997 Oct 13;28(1):5-24
pubmed: 10837562
Endocr Rev. 1989 Aug;10(3):366-91
pubmed: 2673756